A study published in 2023 evaluating the efficacy of Mocetinostat in patients with R/R FL or DLBCL and CREBBP or EP300 mutations, included seven patients in the trial, showed a median PFS of 4.6 months and similar median EFS [174]. The gene discussed is CREBBP; the disease is diffuse large B-cell lymphoma.